The long term risk of myelodysplastic syndromes among anemia patients: A population-based study

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 327-330

  Meytes, D ^a,b   Chodick, G ^a,b   Shalev, V ^a,b   Porath, A ^a,c  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anemia; Epidemiology; Israel; Leucopenia; Myelodysplastic syndromes

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW EXAMINATION; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INCIDENCE; ISRAEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84855948595     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.008     Document Type: Article

References (20)

1. Scott B.L., Deeg H.J. Myelodysplastic syndromes. Annu Rev Med 2010, 61:345-358.
2. Baine B. The WHO classification of the myelodysplastic syndromes. Exp Oncol 2004, 26:166-169.
3. KouidesPA, Bennett J.M. Understanding the myelodysplastic syndromes. The Oncologist 1997, 2:389-401.
4. Hamblin T. Clinical features of MDS. Leukemia Res 1992, 16:89-93.
5. Jadersten M., Hellstrom Lindberg E. Myelodysplastic syndromes biology and treatment. J Intern Med 2008, 10:1365-1387.
6. Strom S.S., Velez-Bravo V., Estey E.H. Epidemiology of myelodysplastic syndromes. Semin Hematol 2008, 45:8-13.
7. Shimizu H., Matsushita Y., Aoki K., Nomura T., Yoshida Y., Mizoguchi H. Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 1995, 61:17-22.
8. Williamson P.J., Kruger A.R., Reynolds P.J., Hamblin T.J., Oscier D.G. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994, 87:743-774.
9. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
10. Maynadié M., Verret C., Moskovtchenko P., Mugneret F., Petrella T., Caillot D., et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996, 74:288-290.
11. Bauduer F., Louis Ducout L., Dastugue N., Capdupuy C., Renoux M. Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leukemia Res 1998, 22:205-208.
12. Neukirchen J., Schoonen W.M., Strupp C., Gattermann N., Aul C., Haas R., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leukemia Res 2011, 35:1591-1596.
13. Germing U., Strupp C., Kungden A., et al. No increase in age specific incidence of myelodysplastic syndromes. Haematologica 2004, 89:905-910.
14. Iwanaga M., Wan-Ling H., Soda M., Takasaki Y., Tawara M., Joh T., et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011, 29:428-434.
15. Malcovati L., Germing U., Kuengden A., et al. Time dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
16. Goldberg S.L., Corral M., Guo A., Mody-Patel N., Pecora A.L., Laouri M. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare Beneficiaries. J Clin Oncol 2010, 28:2847-2852.
17. Mufti G.J., Bennett J.M., Goasguen J., Bain B.J., Baumann I., Brunning R., et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008, 93:1712-1717.
18. Breccia M., Federico V., Latagliata R., Mercanti C., D'Elia G.M., Cannella L., et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leukemia Res 2011, 35:159-162.
19. Oliva E.N., Schey C., Hutchings A.S. Review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res 2011, 1:160-166.
20. Chodick G., Heymann A.D., Rosenmann L., Green M.S., Flash S., Porath A., et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 2010, 21:879-887.